ASCO 2023: Treatment De-Escalation and the Role of Age in HER2+ Breast Cancer
Studies presented at ASCO 2023 answered questions about de-escalating treatment and how age impacts outcomes in HER2+ breast cancer.
Source: cancertherapyadvisor.com
Franco Conte News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Franco Conte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Franco Conte Today - Breaking & Trending Today
One Year of Adjuvant Trastuzumab Remains Standard in HER2+ Early Breast Cancer
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
Source: oncologynurseadvisor.com
One Year of Adjuvant Trastuzumab Remains Standard in HER2+ Early Breast Cancer
Ten-year data from the Short-HER trial suggest that 1 year of adjuvant trastuzumab should remain standard care for HER2+ early breast cancer.
Source: cancertherapyadvisor.com
Long-duration trastuzumab remains standard of care in HER2-positive breast cancer
CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.However, certain patients with low/intermediate HER2-positive early breast cancer may benefit from a shorter, 9-week course of trastuzumab (Herceptin, Genentech), researchers noted.
Source: healio.com